Theralink Technologies Appoints Faith Zaslavsky as Chief Executive Officer
Golden, Colorado, June 27, 2023 (GLOBE NEWSWIRE) — Theralink Technologies, Inc. (OTC: THER) (“Theralink” or the “Company”), a precision oncology company with a novel phosphoprotein and protein assay for breast cancer in the process of merging with IMAC Holdings, Inc. (NASDAQ:BACK), today announces the appointment of Faith Zaslavsky as its new Chief Executive Officer. Ms. Zaslavsky, who has served as the Company’s President and Chief Operating Officer since December 2022, will assume this role effective June 26, 2023, replacing Mick Ruxin, M.D., who will transition to Theralink’s Chief Medical Officer.
Related news for (THER)
- Theralink announces groundbreaking RPPA study by partner GMU – reveals novel therapy options for hard-to-treat breast cancer patients that could lead to significant improvements in response rates
- Theralink® and IMAC Holdings announce receipt and response to the Securities and Exchange Commission comments on the previously filed Form S4
- Theralink® Announces Promising Interim Results on the Implementation of Proteomic Analysis into Inova Schar Cancer Institute’s Molecular Tumor Board
- Theralink Announces Filing of Form S-4; Merger with IMAC Holdings Expected During Q4 2023